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The traits of lipid biocompatibility and versatility have led to many nano- and microparticulate lipid formulations being
engineered, over the last two decades, in the form of spheres and capsules, using solid and liquid lipids as the matrices. This
review describes the main types of lipid nano- and microparticles, as well as their preparation methods, administration routes,
and main fields of application. It will also provide a synthetic overview of the main patents that have been filed. Patenting
activity in the lipid nanoparticle field has been ongoing for 25 years and has been driven by the boom in the use of
nanotechnology as an innovative tool for disease treatment and potential commercial interest in a fully biocompatible vehicle.
Initially, activity was mainly focused on technological aspects, and later focus shifted more to usage and composition. An
increasing number of patents are also being filed by Emerging Countries. However, the most important limitation here is the
low number of marketed products, which is mainly caused by regulatory restrictions and economic reasons.
1. Introduction
Lipid nano- and microparticles show many advantages
over polymeric nanoparticles and have seen widespread
use in the delivery of drugs and actives. They show better
biocompatibility than do polymeric nanoparticles as they
are made of lipids that are similar to their physiological
counterparts [1].
In particular, lipid nanoparticles are a versatile delivery
tool. Besides liposomes and niosomes, which are vesicular
nanostructures that are made up of phospholipids and
amphipathic lipids, respectively, and have a long and safe his-
tory of use, the last two decades have seen many nanoparticu-
late formulations being engineered using solid and liquid
lipids as matrixes. Kinetic stability and rigid morphology
are major advantages that lipid nanoparticles have over
vesicular lipid colloidal systems (liposomes, niosomes, etc.).
Lipid-based nanoparticles overcome the limitations of other
widespread pharmaceutical and cosmetic carriers, the emul-
sions, because they improve the stability and the loading
capacity and prevent the drug/active molecule expulsion dur-
ing storage. However, nanoemulsion systems can be regarded
as a template for nanoparticle generation. Analogously, lipid
nanoparticles are frequently prepared from microemulsions,
which are thermodynamically stable systems [2]. Nanoparti-
cles can be divided into two main families: nanospheres,
which have a homogeneous structure across the particle,
and nanocapsules, which exhibit a typical core-shell struc-
ture. The most important types of lipid nanoparticles are
shown in Figure 1.
1.1. SLN. Solid lipid nanoparticles (SLN) are the best-known
type of nanospheres. SLN are made up of solid lipids with a
photon correlation spectroscopy mean diameter of approxi-
mately between 50 and 1000nm [1]. General ingredients
include solid lipid(s), surfactant(s), and water. The term lipid
is used here in a broad sense and includes triglycerides (e.g.,
tristearin), partial glycerides, fatty acids (e.g., stearic acid),
steroids (e.g., cholesterol), and waxes (e.g., cetyl palmitate).
All classes of surfactants (with respect to charge and molecu-
lar weight) have been used to stabilize lipid dispersions [3].
SLN were developed in the early 1990s and have long been
considered promising drug carrier systems, as they are
physico-chemically stable and can be easily produced on a
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large industrial scale, while raw material and production
costs are relatively low [1]. SLN production is based mainly,
but not solely, on solidified nanoemulsion technologies.
High-pressure homogenization (HPH), high shear homog-
enization, and ultrasonication are used in nanoemulsion
preparation [4, 5].
1.2. NLC. Nanostructured lipid carriers (NLC) are lipid
nanoparticles that are characterized by a solid lipid core
that consists of a mixture of solid and liquid lipid. While
the resulting lipid particle matrix shows melting point
depression compared to the original solid lipid, the matrix
is still solid at body temperature. Different types of NLC
are obtained, imperfect, amorphous, and multiple-type,
depending on the method of production and lipid blend
composition (Figure 1). “In the imperfect type, lipid crys-
tallization is altered by small amounts of oils. In the amor-
phous type, the lipid matrix is solid, but not crystalline
(amorphous state) - this can be achieved by mixing particular
lipids, for example hydroxyoctacosanyl hydroxystearate and
isopropyl myristate. In the multiple type, the solid lipid
matrix contains tiny oil compartments. This type is obtained
by mixing a solid lipid with a higher amount of oil. The
basic idea is that, by giving a certain nanostructure to the
lipid matrix, the active compound payload is increased and
the expulsion of entrapped compounds during storage is
avoided” [6]. NLC can be produced by HPH, and the process
can be modified to yield lipid particle dispersions with solid
contents that range from 30 to 80% [7].
1.3. LDC. Lipid-drug conjugate (LDC) nanoparticles were
developed to overcome the low drug loading capacities of
SLN and NLC for hydrophilic drugs (Figure 1). “In a typical
process, an insoluble drug-lipid conjugate bulk is prepared
either via salt formation (e.g., with a fatty acid), or via cova-
lent linking (e.g., esters or ethers). The obtained LDC is then
processed to create a nanoparticle formulation, using HPH
with the assistance of an aqueous surfactant solution” [6, 8].
1.4. LNC. Lipid nanocapsules (LNC) are the best-known
patented form of lipid core shell nanostructures. They
are composed of an external shell, formed of solid lipids
and emulsifying agents, and an oily core (Figure 1) [2].
Unlike multiple-type NLC, which are made up of a solid lipid
matrix containing numerous oily compartments, into which
drugs tend to partition, LNC possess a sole drug-containing
oily core, which is surrounded by a thin solid coating (core
shell structure).
Moving now to lipid microparticles, the best-known
types are solid lipid microparticles (SLM).
1.5. SLM. “SLM have an equivalent composition to SLN, but
with a larger particle size (>1000 nm), meaning that their
application domains and administration routes may be
different” [6, 9]. In fact, despite their considerable potential
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Figure 1: Scheme of the most important types of lipid nanoparticles.
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as drug carrier systems, SLM have yet to see significant
use, compared to SLN. The main restriction to their use in
parenteral drug delivery is the fact that they are not suitable
for i.v. administration because of size limits. However, their
use in pulmonary drug delivery is promising.
1.6. Patent Overview. A summary of the main types of lipid
particles that are the subject of patent applications is shown
in Table 1. Besides the abovementioned types of nanoparti-
cle, patents concerning polymer lipid hybrid nanoparticles
(PLN) were also included. PLN consist of a mixed lipid
and polymer matrix, in which the polymer is introduced
either to improve nanoparticle characteristics or to facili-
tate drug incorporation. Furthermore, patents concerning
functionalized and variable-shape nanoparticulate systems
are also listed.
2. Preparation Methods
2.1. Lipid Nanoparticle Preparation Methods
(a) Hot Homogenization. HPH has repeatedly proven itself
to be a simple solvent-free technique since the 1950s. It
is well established for the large-scale production of O/W
parenteral emulsions and is available to the pharmaceutical
industry. It has recently been used in the production of
SLN, NLC, and LDC and is the main method for these nano-
particles. However, it involves some critical process parame-
ters, such as high temperatures and pressures (cavitation
forces), that may cause significant thermodynamic and
mechanic stress to the resulting product. For this reason,
and in order to overcome patented methods, alternative
and easy handling preparation methods have seen extensive
investigation [4, 6, 23].
(b) Microemulsion Templates. SLN can be produced from
microemulsion templates. Gasco et al. [24] were the first
researchers to use a microemulsion template for SLN prepa-
ration; “lipids are heated above their melting point and an
aqueous phase, containing surfactants and co-surfactants, is
added under stirring at the same temperature to form a clear
O/W microemulsion” [6]. Multiple W/O/W can be prepared
as well. The microemulsion is then diluted in cool water
(2-10°C), in order to precipitate the nanoparticles.
A few years ago, another microemulsion-based method
was developed for the production of stable SLN [25]. The
authors started from an O/W microemulsion, which con-
sisted of an emulsifying wax as the lipid phase and a poly-
meric surfactant solution as the aqueous phase, which was
kept at a temperature of 37-55°C, according to the melting
point of the emulsifying wax. SLN were obtained by cooling
the undiluted O/W microemulsion at room temperature
while stirring. “An advantage of this invention is that SLN
can be rapidly, reproducibly and cost effectively formulated
at mild operating temperatures from the microemulsion pre-
cursor in a one-step process and contained in a single
manufacturing vessel, vial or container” [6].
(c) Solvent-Based Methods. Solvent-based methods have
been proposed as a means to encapsulate molecules that
present stability and bioavailability issues in various types
of lipid nanoparticles, regardless of the limiting aspects of
solvent toxicology issues. “One of the main advantages of
solvent-based methods is mild operating temperature, which
can be useful for the encapsulation of thermosensitive drugs”
[6]. Solvent displacement is the simplest of these methods. It
is based on dissolving the lipid in a water-miscible organic
solvent (e.g., ethanol, acetone, and isopropanol) and injecting
this solution into water, using a syringe needle, under stir-
ring. Alternative solvent-based methods start with an emul-
sion precursor; O/W or W/O/W emulsions can be prepared
using either a volatile or partially water-miscible organic sol-
vent, which dissolves the lipid. Nanoparticles are formed
when the solvent is removed either by evaporation (solvent
evaporation method) or by water dilution (solvent diffusion
method) [4, 22, 23].
(d) Coacervation Method. A new solvent-free method
(named coacervation) for the preparation of fatty acid SLN
has recently been developed. This technique allows, even
thermosensitive, drugs to be incorporated without using very
complex equipment or dangerous solvents. It is therefore a
cheap method for laboratory and industrial applications
[26]. “It is based on the slow interaction that occurs between
a micellar solution of a fatty acid sodium salt and an acid
solution (coacervating solution) in the presence of a proper
amphiphilic polymeric stabilizing agent” [6]. Fatty acid
nanoparticles can be precipitated by lowering the pH.
(e) Supercritical Fluid Technology. Supercritical fluid (SCF)
technology has attracted increasing levels of interest, in
recent years, for the benefits that it provides as a nanoparticle
production method. The SCF condition is obtained above a
substance’s critical pressure and temperature, wherein its
solubility in the fluid can be modulated by relatively small
changes in pressure. Carbon dioxide is the most widely used
Table 1: The most important patents for types of lipid nano- and
microparticles.
Lipid particle type Patent number Ref.
SLN
EP0605497 [10]
WO9614830 [11]
NLC EP00/04111 [12]
LDC
WO00/67800 [13]
US6770299 [14]
WO2010107487 [15]
LNC
WO0164328 [16]
WO2009037310 [17]
SLM US20070053988 [18]
Others
Anisometrical SLN WO9420072 [19]
PLN
US20080102127 [20]
WO2011116963 [21]
Functionalized LNC WO2010113111 [22]
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SCF due to its low critical point, of 31°C and 74 bar, its safety
and low cost. Two main SCF-based methods have been
developed for SLN production: the SCF extraction of emul-
sions (SFEE) and gas-assisted melting atomization (GAMA).
In SFEE, lipid nanosuspensions are obtained through the
SCF extraction of the organic solvent from O/W emulsions
[27]. Solvent extraction into supercritical CO2 leads to the
precipitation of lipid/drug material, which is dissolved as
composite particles. One of the advantages of this technique
is the high solvent extraction efficiency of supercritical CO2,
compared to conventional methods, which allows the solvent
to be quickly and completely removed and a more uniform
particle size distribution to be achieved (Figure 2).
In the GAMA method, “lipids are melted in a
thermostated mixing chamber (CM), where they are melted
and kept in contact with supercritical CO2” [6]. Then, a valve
is opened at the bottom of the CM, where the lipid-saturated
mixture is forced through a nozzle. The rapid depressuriza-
tion of the mixture creates a high degree of supersaturation
and leads to the precipitation microparticles, which are gath-
ered by a collection system and dispersed in water via
vortexing and ultrasound treatment to give the nanosuspen-
sions (Figure 3) [28]. This method is solvent-free, making it
advantageous for industrial processes.
(f) Microwave Assistance. Microwaves can assist in forming
the microemulsion template used for nanoparticle prepara-
tion [31] and in the direct production of nanoparticles [32].
In this second case, using a microwave reactor is simple,
quick, cheap, and sustainable. This technology facilitates
the one-pot production of the particles, in one or two steps
and in a closed system. Furthermore, it does not use organic
solvents or large volumes of water.
(g) Dual Asymmetric Centrifuge. Lipid nanoparticles can be
prepared in a dual asymmetric centrifuge (DAC) [33]. DAC
differs from conventional centrifugation as the sample is also
rotated around its own vertical axis. While conventional cen-
trifugation constantly pushes the sample material outwards,
this additional rotation constantly forces the sample material
towards the centre of the centrifuge. This unique combina-
tion of two contra-rotating movements results in shear forces
and, thus, in efficient homogenization.
(h) Membrane Contactor. Another method for producing
SLN, one which makes use of a membrane contactor, has
been developed [34]. A functioning module has been pro-
duced. It includes a ceramic membrane (0.1, 0.2, or 0.45μm
pore size) “that separates the aqueous phase, which is allowed
to circulate tangentially to the membrane surface, and the
lipid phase” [6]. The lipid phase is melted in a pressurized
vessel and forced through a tube towards the membrane
pores placed in the module, leading to small droplet forma-
tion, which are detached from membrane pores by tangential
water flow. SLN are formed after the obtained water disper-
sion is cooled (Figure 4). The proposed method permits the
continuous preparation of large volumes and is therefore
claimed to be highly suitable for industrial scale-up.
(i) Phase Inversion Temperature. The phase inversion tem-
perature (PIT) method is usually employed for the prepa-
ration of nanoemulsions. The PIT concept exploits the
specific ability of some polyethoxylated surfactants to change
their affinities for water and oil as a function of temperature.
“The use of such a surfactant type leads to an emulsion
inversion from an O/W macroemulsion to a W/O emulsion
when the temperature is increased above the PIT” [6]. An
O/W nanoemulsion is then formed when the temperature
decreases below the PIT. The PIT method has been
employed for LNC preparation, too, with an internal liquid
or semi-liquid oil core and an external lipid layer that is solid
at room temperature [2]. It has recently been adapted for
SLN preparation, too. The aqueous phase, containing NaCl,
and the oil phase, made up of solid lipids and nonionic sur-
factants, are separately heated at ~90°C (above the PIT).
“The aqueous phase is then added dropwise, at constant tem-
perature and under agitation, to the oil phase, in order to
obtain a W/O emulsion. The mixture is then cooled to room
temperature under slow and continuous stirring. The turbid
mixture becomes clear at the PIT, and, below the PIT, an
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Figure 2: Scheme of the counter-current column for the extraction
of an emulsion using SCF. Vessel containing supercritical fluid
(110), supercritical fluid source (112), emulsion source (114),
vessel first and second outlet (120, 122), vessel axis (128), vessel
sidewalls (130), vessel first and second ends (132, 134), vessel
inner surface (136), extraction chamber (138), vessel headspace
(142), stainless steel frit (144), vessel inlet (146), backpressure
regulator (162), and release valve (168) [29].
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O/W nanoemulsion is formed, which turns into SLN below
the lipid melting point” [6, 36].
2.2. Lipid Microparticle Preparation Methods. SLM can be
obtained in suspension or in a solid powdered state, depend-
ing on the technique used [37].
(a) Melt Dispersion. The melt dispersion technique is
employed for SLM formulation. SLM can be obtained from
either O/W or multiple W/O/W emulsions, depending on
the chemical nature of the drug. In the case of the O/W pre-
cursor, the lipophilic drug is dissolved into the melted lipids,
which are emulsified with a hot surfactant solution in water
using a high shear mixer. Lipid microparticles are then solidi-
fied by cooling at room temperature [38]. In the case of the
W/O/W precursor, a primaryW/O emulsion is formed by dis-
solving the drug in the water phase; this is then placed into
contact with an external aqueous phase at the same tempera-
ture. The resulting W/O/W multiple emulsion is then cooled
to room temperature to obtain the microparticles [39].
(b) Cryogenic Micronization. “In cryogenic micronization,
lipid matrices that are either obtained via melt dispersion
(the drug is mixed with a melted lipid) or solvent stripping
(drug and lipid are dissolved into a solvent mixture under
stirring)” [6], stored at −80°C, and then micronized in a cus-
tomized apparatus under the effect of liquid nitrogen. This
technique can only be used for the production of microparti-
cles of 5-5000μm in diameter [40].
(c) Spray-Drying. The spray-drying of lipid particles is per-
formed using an organic solvent solution as the feed. This
solution is evaporated to a dried particulate form in a
one-step process [41].
(d) Electrospray. The electrostatic atomizer in the electro-
spray technique includes a nozzle that is connected to a
high-voltage power supply and supplied with the liquid to
be atomized. The lipid solution, which is in an organic sol-
vent, is contained in a syringe, and a metal capillary is con-
nected to a high-voltage power supply and functions as an
electrode. A metal foil collector is placed opposite the capil-
lary and functions as a counter electrode. Solid lipid particles
can be formed by evaporating the solvent from the droplets
that are produced by the electrical field [42].
(e) Spray-Congealing. “In the spray-congealing method,
lipids are heated to a temperature above their melting point”
22
15
19
5
18
8
7
50
16
23
50′
1110
12
2
3
TC
14
21
20
PI
TI
TC
Figure 3: Scheme of the apparatus for producing SLN via the GAMA process. Pump (2), supercritical CO2 supplier (3), melting chamber (4),
100mm diameter nozzle (5), air supplier (7), pressure reducer (8), mixing device (10, 11), electrical resistances (12, 15, 16, 18, and 23), heating
system (14), precipitation vessel (19), filter (20), compressor for tangential air flux (21), spraying pump (22), on–off valves (50, 50I), pressure
indicator (PI), temperature indicator (TI), and temperature controller (TC) [30].
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[6]. Hot lipids are atomized through a pneumatic nozzle into
a vessel, which is held in a carbon dioxide ice bath. The
microparticles that are obtained (50-500μm) are then dried
under vacuum at room temperature [43].
2.3. Patent Overview. An overview of the most important
technological patents that concern the abovementioned
preparation methods, both for lipid nano- and microparti-
cles, is shown in Table 2.
3. Administration Routes
Dermal administration is an area of great potential for lipid
nano- and microparticles, and its short time-to-market
makes it especially promising for use in cosmetic formula-
tions. The distinct advantages of the cutaneous drug delivery
of lipid particles are the ability to protect chemically labile
ingredients against chemical decomposition, the ability to
modulate drug release, and the ability to form adhesive lipid
films on the skin, providing a possible occlusive effect [64].
Their particle size and therapeutic objectives mean that
lipid nano- and microparticles can be used for all parenteral
applications: from intra-articular to intramuscular, subcuta-
neous, and intravenous administration [65]. Because of their
small size, lipid nanoparticles can be injected intravenously
and used to target drugs to specific organs. However, they
are cleared from circulation by the liver and spleen, as is
the case with all intravenously injected colloidal particulates.
“Stealth” lipid nanoparticles that are able to avoid the reticu-
loendothelial system (RES) can be obtained by coating their
surface with polyethylene glycol (PEG).
Lipid nano- and microparticles can be orally adminis-
tered in the form of aqueous dispersions or, alternatively,
after transformation into a solid dosage form, such as tablets,
pellets, capsules, or powders in cachets. Aqueous particulate
dispersions can be used as a granulation fluid for the produc-
tion of tablets. Alternatively, they can be transformed into a
powder (e.g., by spray-drying or freeze-drying) and added
to a tableting powder mixture or used to fill hard gelatin cap-
sules. Lower production costs mean that spray-drying may be
the preferred method for transferring lipid particulate disper-
sions into powders [1]. If administered via the oral route,
lipid nano- and microparticles can help drug solubilization
in the gastrointestinal tract (GIT). In fact, they can retain a
poorly soluble substance in a solubilized state and enhance
solute-solvent interactions, especially after being mixed with
endogenous solubilizers, such as bile acids or phospholipids.
Moreover, their protective effect, coupled with their sus-
tained and/or controlled release properties, prevents drugs
(macromolecules in particular) from undergoing premature
degradation and improves their stability in the GIT [66]. Fur-
thermore, nanosized particles can be taken up by the M cells
of Peyer’s patches, which in turn enables the carrier system to
bypass first-pass effect metabolism and undergo lymphatic
absorption. The reduction of side effects (i.e., the stomach
toxicity of nonsteroidal anti-inflammatory drugs (NSAID))
and taste masking are also two relevant goals for the oral
administration of lipid particles [67].
The pulmonary application of lipid microparticles is also
promising as they show good aerosolization properties and
excellent stability when nebulized as a liquid formulation.
SLM that are obtained in the solid form (i.e., by spray-drying)
are suitable for this application method thanks to their aero-
dynamic size. Proper lipid particle design should avoid them
being deposited in the bronchial regions. In fact, whereas
rapid bronchial clearance may lead to drug concentrations
below therapeutic levels, the retention of lipid particles in
the lungs contributes to prolonged drug release. Higher
drug bioavailability and longer therapeutic effects can thus
be achieved, resulting in reduced dosage and prolonged
dosing intervals. Lipid particles may therefore be able to
offer a broad range of benefits in the local treatment of
severe airway diseases, as well as for systemic drug delivery.
In addition, the pulmonary administration of lipid matrices
has been demonstrated to present low toxicological poten-
tial in several studies. However, no investigations into the
long-term effects of repeated pulmonary administration
have been performed [68].
Lipid nanoparticles can improve the therapeutic effi-
ciency, compliance, and safety of ocular drugs, administered
via several different routes, to both the anterior and posterior
segments of the eye. They are suitable for topical adminis-
tration because of their ability to increase corneal residence
time and thus overcome corneal barriers. Moreover, despite
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Figure 4: Scheme of the membrane contactor module. A (lipid
phase), B (aqueous phase), M (porous membrane), 1 (pressurized
vessel containing the lipid phase), 11 (thermostated bath), 12
(thermostat), 2 (nitrogen bottle), 3 (manometer), 4 (vessel
containing the aqueous phase), 41 (thermostated bath), 42
(thermostat), 5 (stirrer), 6 (pump), 7 (tangential flow filtration
unit), and 8-9 (manometer) [35].
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effective drug delivery to the posterior segment of the eye
being challenging and alternative routes of administration
(periocular and intravitreal) generally being required, lipid
nanoparticle formulations that are optimized for the retina
should aim at controlling drug release and reducing adminis-
tration frequency [69].
3.1. Patent Overview. Several usage patents on specific
administration routes for lipid particles have been filed: a
summary is shown in Table 3.
4. Therapeutic and/or Technological Aims
Lipid nano- and microparticles have been proposed for
drug and active delivery with several therapeutic and/or
technological aims [4, 118, 119]; the most relevant are
described below.
4.1. Cancer Therapy. The rationale of using lipid nanoparti-
cles for anticancer drug delivery is based on a number of
physiological mechanisms. A tumor is often associated with
defective, leaky vascularization that results from poorly regu-
lated angiogenesis. Submicron-sized particulate matter may
thus preferentially extravasate into the tumor and be retained
there, because of the so-called enhanced permeability and
retention (EPR) effect. EPR-effect-based passive tumor tar-
geting can be achieved using properly designed lipid nano-
particles, which can avoid opsonization by the complement
and consequent elimination by the RES. “Long-circulating”
lipid nanoparticles are designed to have reduced particle
sizes and hydrophilic surfaces (they are coated with hydro-
philic polymers) for this very reason [120]. Moreover,
surface-engineered lipid nanoparticles can be used for active
targeting to increase cancer cell-selective cytotoxicity. This
can be done by exploiting differences in the surface antigens
and receptors of cancer and healthy cells [96]. Finally,
multidrug resistance (MDR) is an important limitation of
anticancer drug therapy. MDR is mainly associated with
P-glycoprotein (P-gp), which acts as an efflux pump from
the cell for many drugs (anticancer agents, antibiotics, etc.).
Lipid nanoparticles can help to overcome the MDR phenom-
enon, probably because they carry encapsulated drugs into
cancer cells via endocytosis, thereby bypassing the P-gp drug
efflux mechanism [120].
4.2. Overcoming the Blood-Brain Barrier. Lipid nanoparti-
cles have frequently been proposed as vehicles that can
overcome the blood-brain barrier (BBB). The BBB acts as
a physical barrier and regulates the passage of selected mol-
ecules between the bloodstream and the brain. In particular,
the tight junctions between the endothelial cells mean that
the passive diffusion of solutes through the paracellular
pathway is very limited. Lipid nanoparticles can be useful
in the brain uptake process at various levels, as they can
(i) stabilize drugs against chemical degradation in biological
fluids, (ii) increase permanence in the bloodstream and
Table 2: Most important patents that concern the preparation methods for lipid nano- and microparticles.
Preparation method Patent number Lipid particle type Size range Ref.
HPH
WO0103670
SLN, NLC, and LDC 50-1000 nm
[44]
WO2015148483 [45]
Solvent evaporation WO2008013785 SLN <240 nm [46]
Solvent displacement
WO2011127255 SLN <150 nm [47]
CN201010112202 SLN, NLC [48]
Microemulsion templates
US5250236
SLN 50-300 nm
[49]
US7153525 [50]
IN127/DEL/2012 [51]
Coacervation WO2008149215 SLN 200-1000 nm [52]
SFEE WO2004004862 SLN 20-90 nm [29]
GAMA WO2007028421 SLN, SLM 0.2-20 μm [30]
Microwave assisted WO2018109690 SLN, NLC 60-300 nm [53]
DAC EP1838286 SLN 15-200 nm [54]
Membrane contactor WO2007000531 SLN 100-200 nm [35]
Temperature phase inversion
WO2009004214
LNC 30-100 nm
[55]
WO2011036234 [56]
Melt dispersion
US2010233344
SLM 1-250 μm
[57]
WO2010075065 [58]
Cryogenic micronization US2004091522 SLM 1-500 μm [59]
Spray-drying
WO2006066367
SLN, SLM 0.3-10 μm
[60]
WO0185137 [61]
Electrospray ITTO2008A000475 SLN, SLM Nearly 1 μm [62]
Spray-congealing WO9603979 SLM 50-2000 μm [63]
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Table 3: Most important patents concerning the use of lipid nano- and microparticles for specific administration routes.
Administration
route
Patent number
Lipid
particle type
Aim Ref.
Dermal
WO2010051918 SLN, SLM Codelivery of metal nanoparticles and SLN/SLM in dermal formulations [70]
WO2010112749 SLN Dermal composition for minoxidil delivery [71]
WO0103652 SLN
Increase in UV filter efficacy and stability through
nanoparticulate delivery
[72]
WO2008041116 SLN Transdermal delivery of drugs with short half-lives and/or high activity [73]
WO2004098555 SLN Targeted release of fragrances and aromas [74]
US20100104522 NLC
Skin delivery of omega-3 fatty acid for antiaging and
moisturizing purposes
[75]
WO2009111852 SLN
Formulation of retinoids in the form of ion pairs with lipophilic
amines, suitable for skin delivery
[76]
US20130034612 LNC Avermectin delivery for acne rosacea treatment [77]
WO2014077712 SLN Roxithromycin topical delivery to stop hair loss or for acne treatment [78]
WO2017143421 SLN
Cosmetic composition aimed at the sustained release of substances
that repel insects
[79]
BR1020140173161 SLN
A method to obtain trans-resveratrol- (RES-) loaded SLN and their
use in the antitumor therapy of melanoma
[80]
IN611/MUM/2011 SLN
Terbinafine-loaded SLN incorporated into a gel with enhanced
skin deposition and improved antifungal activity
[81]
IN149/CHE/2014 SLN Improved treatment of psoriasis [82]
IN3658/MUM/2014 SLN
Mupirocin SLN incorporated into a Carbopol-based gel to enhance
efficacy in skin infection treatment
[83]
IN201711046022 SLN
SLN used as a carrier in the development of transdermal patches
for diltiazem permeation
[84]
IN428/DEL/2010 SLN
Topical antioxidants loaded in SLN as therapeutics to combat
photoageing
[85]
IN1394/DEL/2011 SLN
Gel loaded with vitamin D analogues and corticosteroids entrapped
in SLN to treat psoriasis
[86]
IN26/KOL/2014 SLN
Acyclovir-loaded SLN to avoid systemic drug penetration through
the skin
[87]
WO2012127037 NLC
Vitamin D and corticosteroid coloaded into NLC in order to increase
drug accumulation in the skin
[88]
Parenteral WO2009102121 SLN
Cacao butter nanoparticles that are suitable for the parenteral
administration of drugs
[89]
Oral
US2011082214 SLN Preparation of tablets from SLN suspensions [90]
EA200900215 SLN
Treatment of tuberculosis and diseases mediated by Helicobacter
pylori via the peroral administration of SLN loaded with rifabutin
and rifampicin
[91]
WO2014140268 SLN
Delivery of food grade actives in SLN (antimicrobial, antioxidants,
polyphenols, vitamins, etc.)
[92, 93]
CN201510071840 SLN
Increase in docetaxel oral bioavailability via the use of freeze-dried
quaternary ammonium salt chitosan-modified SLN
[94]
KR20150093510 SLN Formulation of docetaxel in SLN for oral delivery [95]
WO2015039199
SLN, LNC, and
nanoemulsions
Improvement of the dissolution profile of benznidazole with
increased bioavailability
[96]
CN200910192553 SLN
Increase in the oral uptake of lappaconitine-loaded SLN, prepared
using HPH
[97]
CN200910034968 SLN
Increase in Tripterygium glycoside dissolvability, improving oral
bioavailability
[98]
CN200910027782 SLN
Solving the problems of the low solubility, low dissolution rate,
and low bioavailability of finasteride
[99]
CN201410531574 SLN Increased bioavailability of asiatic acid [100]
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thus indirectly favor translocation to the brain, and (iii)
directly trigger endothelial cells, thus inducing endocytosis,
which may also be receptor-mediated via an active target-
ing mechanism. Although plain lipid nanoparticles have
been used as vehicles to overcome the BBB, research is cur-
rently evolving towards targeted lipid nanoparticles, which
improve interaction selectivity between nanoparticles and
endothelial cells [121].
4.3. Gene Therapy. Lipid nanoparticles can be successfully
used as nonviral vectors for gene therapy. Gene therapy is
achieved by introducing genetic material (plasmid DNA,
pDNA) into target cells, in order to induce protein expression,
or, alternatively, by using either antisense oligonucleotides
(ASO) or small interfering RNA (siRNA) as transcription
and/or translation inhibitors to silence defective genes.
Naked nucleic acids are easily digested by enzymes in biolog-
ical fluids. Moreover, cell internalization does not happen
spontaneously because both nucleic acids and cell mem-
branes have negatively charged surfaces, resulting in nonef-
fective therapeutic responses. Even if viral vectors are the
most effective carriers, nonviral vectors are safer, have lower
costs, are more reproducible, and do not present a DNA size
limit. The use of lipid nanoparticles as nonviral vectors in
gene therapy entails the use of positively charged lipids that
can electrostatically bind nucleic acids. This is beneficial for
transfection because condensation facilitates nucleic acid
mobility, protecting them from environmental enzymes,
while the cationic character of the vectors allows for interac-
tion with the negatively charged cell surfaces [122].
4.4. Protein and Peptide Delivery. Lipid nano- and micro-
particles are widely employed for protein delivery. The
therapeutic use of peptides and proteins is restricted by
their high molecular weight, hydrophilic character, and lim-
ited chemical stability, which lead to low bioavailability,
poor transfer across biological membranes, and low stabil-
ity in the bloodstream. Most peptides and proteins available
are delivered via injection, but their short half-life means
that repeated doses, which are expensive, painful, and
poorly tolerated by patients, are required. Recent years have
seen significant effort being directed towards needle-free
Table 3: Continued.
Administration
route
Patent number
Lipid
particle type
Aim Ref.
CN201010224865 NLC
Agglutinin-modified and glutaraldehyde cross-linked NLC for the
oral delivery of insoluble compounds
[101]
IN430/DEL/2004 SLN
Antitubercular drug (rifampicin, isoniazid, and pyrazinamide)
association for oral delivery
[102]
IN3139/DEL/2005 SLN Improved bioavailability of drugs via gut lymphatic system absorption [103]
IN3310/DEL/2012 SLN Cocoa-butter SLN loaded with tenofovir with controlled release [104]
IN3356/DEL/2012 SLN
Improved bioavailability of rifampicin and limited drug degradation and
interaction with isoniazid in the acidic environment of the stomach
[105]
IN3509/DEL/2012 SLN
Azathioprine-loaded SLN with prolonged release with the aim of
colon delivery
[106]
IN264/DEL/2013 SLN
Lercanidipine enhanced oral bioavailability and prolonged
release of action
[107]
IN1365/MUM/2014 SLN Sustained release of glipizide [108]
IN3329/MUM/2010 SLN
Treatment of fungal infections and leishmaniasis with amphotericin
B-loaded SLN
[109]
IN2194/CHE/2010 SLN Improved oral bioavailability of olanzapine [110]
IN2960/DEL/2014 SLN
SLN loaded with the extract of the aerial portion of Ficus benjamina
are incorporated into floating tablets
[111]
Pulmonary WO2009050217 SLM
Spray-dried powder for dry inhalers with enhanced flow and
dispersal properties
[112]
Ocular
WO2004039351 SLN Suitable eye-drop composition for the treatment of ocular diseases [113]
WO2012085318 SLN Treatment of ocular diseases using nucleic acid-complexed SLN [114]
WO2016055976 SLN, NLC
Silibinin-loaded mucoadhesive SLN, NLC, and calixarenes,
with sustained drug release, for the treatment of ocular
neurodegenerative diseases
[115]
IN2339/DEL/2014 SLN
Statin-loaded SLN for topical application and the treatment
of age-related macular degeneration, glaucoma, and other
ocular inflammatory diseases
[116]
CN201610005904 NLC
NLC - intraocular lens system, which is loaded with
anti-inflammatory drugs and antibiotics, in order to prevent
or treat cataract surgery complications
[117]
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alternatives to the administration of these biomacromole-
cules that mainly, but not exclusively, make use of the oral
route. However, buccal, nasal, pulmonary, and transdermal
administration routes have also been investigated [98].
Lipid nano- and microparticles may be useful in peptide
and protein delivery due to the stabilizing and absorption
promoting effect of lipids. Moreover, particulate carriers
have been sought as vehicles for protein antigens for some
time. Extensive work has been carried out in the area of
vaccine formulation using lipid particles, since most peptide
or protein antigens are ineffective for mucosal immuniza-
tion due to proteolytic degradation at mucosal sites [123].
4.5. Antioxidant and Vitamin Delivery. Lipid nano- and
microparticles have great potential for efficiently protect-
ing antioxidants and vitamins against degradation (they
are often light- and oxygen-sensitive). Furthermore, they
can improve skin penetration. The use of lipid particles as
dermal delivery systems may therefore be regarded as a
convenient strategy with which to enhance the topical
effectiveness of antioxidants. Some skin care products that
contain antioxidant-loaded lipid nanoparticles have already
been marketed [124]. Furthermore, antioxidants are fre-
quently characterized by low bioavailability following oral
administration. Their entrapment within lipid nanoparticles
can help to increase intestinal uptake and thus improve their
pharmacokinetics [125].
4.6. Diagnostics Delivery. Important preclinical studies
have recently been carried out in the diagnostic field using
lipid nanoparticles that are set up for positive contrast
magnetic resonance imaging (MRI). These systems include
MnCl2, gadolinium(III) diethylenetriaminepentaacetic acid
(Gd-DTPA), and the manganese(II) equivalent (Mn-DTPA).
Near infrared (NiR) dyes have also been conjugated to lipid
nanoparticles, such as Alexa Fluor™ 488. However, a new
concept is currently gaining attention in cancer therapy: the
conjugation of therapeutic agents and diagnostic tools in
the same multimodal theranostic nanoparticle [126].
4.7. Patent Overview. Table 4 provides a summary of the
most important patents that concern the usage and composi-
tion of lipid nano- and microparticles that are dedicated to
specific therapeutic or technological aims.
5. Market Concerns
The last few decades have seen a gradual and significant
increase in the number of registered patents that concern
lipid nano- and microparticles. On the other hand, it is worth
noting that most formulations that have beenmarketed belong
to the cosmetic field. Only three lipid-nanoparticle-based
oral formulations are currently marketed, but one of them
is licensed as a “nutraceutical” product (Table 5). However,
while it can be estimated that more than 500 cosmetic prod-
ucts that contain NLC are present worldwide, they are hard
to count as NLC are often not listed as NLC products on the
International Nomenclature of Cosmetic Ingredients (INCI)
list [182].
The efforts of researchers from all around the world are
increasing, as demonstrated by the amount of research pub-
lished in recent years. This increase is due to the potential
industrial applications of lipid nano- and microparticles
and the fact that they can boast of solvent-free and easily
scaled-up preparation methods, the use of biocompatible
materials, etc. These data highlight a general trend in the
patenting activity of lipid particles; in the 1990s, the scien-
tific community, especially in Europe, showed increased
interest in innovative preparation techniques for lipid nano-
particles, while, from the beginning of the new millennium,
patenting activity shifted mainly towards drug delivery
applications, and researchers from Emerging Countries
became progressively more involved. Some small and
medium industries (SMEs) and spin-off companies that ded-
icate their core business to lipid nanoparticles have also
arisen: Italian Nanovector Srl, Russian Nanosystem Ltd.,
German PharmaSol GmbH, Spanish Lipotec SA, Indian
Transgene Biotek Ltd., and Korean AmorePacific Corp are
some examples [189, 190]. In fact, SMEs can be seen to be
the main driving force for innovation in this field, even more
so than large companies [182].
However, there is a large gap between the number of lit-
erature articles and patents despite the increasing interest in
lipid carriers [189, 190]. Furthermore, an evaluation of the
status of existing patents reveals that only a few have reached
the granted status, while the remainder are still classified as
applications. This is even more evident when we compare
filed patents and marketed products.
There are a number of reasons why many patented
works in this area remain at an initial stage and are not
translated into industrial products; regulatory concerns can
play a key role. Thus, despite the huge amount of research
carried out on the use of lipid nanoparticles for dermal
administration [191], regulatory aspects mean that all mar-
keted products for dermal administration are licensed as
cosmetics (Table 5); in fact, cosmetic products are easier
to process in terms of time and economic investment as
they do not require clinical evaluation.
In fact, the exponential development of nanotechnology
in recent years has raised not only high hopes but also a num-
ber of safety, ethical, and, consequently, regulatory questions
that can significantly hamper the marketing process [192].
From a regulatory point of view, lipid nanoparticles undergo
the general regulatory concerns of nanomaterials.
Harmonizing the definition of nanomaterials, as used by
researchers, producers, and regulators, is a stringent neces-
sity. According to the European Commission Recommenda-
tion on the definition of a nanomaterial (2011/696/EU),
100 nm is the demarcating upper limit as it refers to the size
around which the properties of materials can change signifi-
cantly from conventional equivalents. Lipid nanoparticle
sizes tend to exceed 100 nm, but particles that are greater
than 100nm, in the submicron size range, can still offer
“nano-related properties” due to higher superficial energy,
despite having a lower capacity to penetrate through mem-
branes and skin [193].
Classification may depend on scientific discipline and
on the impact of nanomaterials on the human organism,
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Table 4: Most important patents that concern the specific therapeutic/technological aims of lipid nano- and microparticles.
Therapeutic/
technological aim
Patent number
Lipid
particle
type
Drug/active
delivered
Brief description Ref.
Cancer therapy
FR2935270 SLM Temozolomide
Galenic form of SLM formulated with temozolomide
in a lipid matrix
[127]
WO2006128888 SLN Cholesteryl
butyrate,
propionate
SLN, made up of cholesteryl butyrate and propionate
as a lipid matrix, are used for the prevention and
treatment of inflammatory pathologies
[128]
US6685960 SLN
SLN, made up of cholesteryl butyrate and propionate
as a lipid matrix, are used for tumor treatment
[129]
WO2005092298 SLN
Platinum
compounds
The loading of platinum derived compounds in SLN
is obtained using a warm microemulsion method
[130]
WO2004071498 LNC
P-glycoprotein
inhibitor
LNC are stabilized by surfactants that can act as
P-glycoprotein inhibitors and reduce tumor
drug resistance
[131]
CN200910065523 SLN Cucurbitacin
A cucurbitacin-loaded SLN preparation method
is disclosed, in which the formulation maintains
its stability
[132]
CN201110022618 PLN Adriamycin
The loading of adriamycin into SLN is achieved
via complexation with polyanion sodium alginate,
leading to a sustained release formulation
[133]
CN200810041865 SLN Docetaxel
Long-circulating docetaxel-loaded SLN are
formulated
[134]
WO2014206093 SLN
Chinese herbal
compound
The loading of Chinese herbal antitumor compounds
into SLN significantly improves their bioavailability,
reducing dosage and increasing therapeutic effects
[135]
IN421/DEL/2008 SLN Paclitaxel Controlled delivery [136]
Brain delivery
US2010247619 NLC Riluzole
Medicinal formulations are prepared to treat
amyotrophic lateral sclerosis and multiple sclerosis
[137]
US6514519 SLN
Octadecyl-2-
methyl-sn-glycero-3-
phosphorylcholine
(edelfosin)
SLN are loaded with edelfosin, which is suitable
for the treatment of brain tumors and can also
be administered orally
[138]
WO9920256 SLN —
BBB targeting of SLN is obtained via either specific
protein linkages or absorption onto the SLN surface
[139]
WO2011019954 SLN —
SLN delivery to the brain is achieved via the
perilymphatic fluid of the inner ear, through
the cochlear aqueduct
[140]
WO9927918 SLN —
Small-sized SLN, obtained from warm
microemulsions,
can cross the BBB
[141]
US20100129431 SLN Idebenone
Injectable nanoparticles that are loaded with
idebenone can protect from neuronal damage and
improve recovery after brain trauma
[142]
CN201610002634 SLN Aripiprazole
Aripiprazole-loaded SLN for injection have high
bioavailability, low toxic and side effects, and
controlled-release targeting properties
[143]
CN201610262638 SLN
Antidepressant
composition
A mixture of curcumin, folic acid, lecithin, and
HU-211 is loaded into SLN, with increased
bioavailability
[144]
IN201621034343 SLN Tapentadol
In situ gel composition of loaded SLN for
nose-to-brain delivery
[145]
IN1251/MUM/2012 NLC Ubidecarenone Treatment of neurodegenerative disorders [146]
IN2009/MUM/2012 SLN Granisetron SLN-cyclodextrin complex for nose-to-brain delivery [147]
IN3451/DEL/2012 SLN Carbidopa
Bionanoparticles and SLN to target the brain
via administration through the ear cavity
[148]
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Table 4: Continued.
Therapeutic/
technological aim
Patent number
Lipid
particle
type
Drug/active
delivered
Brief description Ref.
Gene therapy
WO02051446 SLN Nucleic acids
Cationic SLN are employed to condense nucleic
acids on their surface
[149]
WO2009051451 LDL-like
ASO, siRNA,
and p-DNA
Cationic LDL-like nanoparticles can complex nucleic
acids and be used to treat liver diseases
[150]
WO2008096321 LNC siRNA, p-DNA
A complex between a cationic lipid and a nucleic
acid is loaded into the inner oily core of LNC
[151]
WO2005120469 SLN
Anti-VEGF
ASO
An anti-VEGF nucleotide is complexed with cationic
SLN in order to inhibit angiogenesis, especially in
the posterior segment of the eye
[152]
WO2011015701 SLN p-DNA
In order to achieve transfection, p-DNA is complexed
with SLN that is functionalized with a cationic lipid or
peptide, a nonionic surfactant, and a polysaccharide
[153]
WO2017015552 SLN siRNA
A solid lipophile siRNA cargo can be obtained using
cationic SLN, a dextrin, and a sugar
[154]
WO20040530056 SLN p-DNA
A vaccine formulation is obtained by coating SLN
with a nucleic acid that encodes for an
immunogenic peptide, in the presence of a
cholera toxin, used as an adjuvant
[155]
IN201611003140 SLN
p-DNA,
siRNA
Two-step process to entrap pDNA and siRNA
within the lipid matrix of SLN
[156]
Protein and
peptide delivery
WO9956733 SLN Cyclosporine
When cyclosporine is loaded into SLN, a better
pharmacokinetic profile, compared to commercial
formulations, is obtained after oral administration
[157]
CN201610203074 SLN Sirolimus
Sirolimus-loaded SLN are employed as a nonirritant
topical formulation for the treatment of multiple
immune and inflammatory skin diseases (atopic
dermatitis, eczema, dermatitis, lichen planus,
psoriasis, vitiligo, rosacea, and sarcoidosis)
[158]
WO2015007398 SLN Antibody
Antibodies are loaded into SLN through
hydrophobic ion pairing
[159]
WO02051390 SLN
LHRH
antagonist
LHRH-antagonist peptide is loaded into
HPH-produced SLN
[160]
WO2009080164
SLM
Growth
hormone
Lipid-coated microparticles that are loaded with
growth hormone are obtained by spray-drying,
without denaturing the protein
[161]
WO2010017965
Lipid-coated microparticles that are loaded with
growth hormone are obtained by spray-drying and
spray congealing, without denaturing the protein
[162]
WO0071077
SLN
Antigen for
vaccine
SLN are employed as stable and biocompatible
adjuvants for vaccines
[163,
164]WO0071154
WO2017097783
Aminoalkyl glucosaminide phosphate is
employed as a vaccine adjuvant in antigen-
complexed cationic SLN
[165]
WO0164254 SLM
Antigen-loaded spray-dried SLM are functionalized
with a ligand that is specific for antigen-presenting
cells, inducing immune responses
[166]
CN201010522545 SLN Catalase
A two-step emulsion process from a multiple
W/O/W emulsion is used to load catalase into SLN,
greatly increasing the stability of the enzyme and
prolonging its effective activity duration
[167]
WO2007113665 PLN
Various therapeutic
peptides
Lectin-functionalized PLN are loaded with
therapeutic peptides in order to increase oral uptake
and/or immunization
[168]
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but also on environmental exposure. In particular, Euro-
pean Regulation on cosmetic products (CE n.1223/2009)
associate the concept of nanomaterial insolubility and per-
sistence to dimensional limits (100 nm) [194], whereas the
efficacy and/or safety assessment of nanomaterials in
medicinal products is still based on case-by-case evaluation
because of the complexity of these systems. The European
Medicines Agency (EMA) issued a reflection paper on
nanotechnology-based medicinal products for human use,
in 2006, which also included an official definition of nanome-
dicine, as being up to a size of ca. 100 nm [195]. However,
nanotechnology-based products that have been investigated
for pharmaceutical applications have broader size ranges
than the proposed definition, inducing the EMA to also
include all “structures” with sizes of less than 1000 nm that
are designed to have specific properties [196] and can
improve site-specific drug delivery and significantly alter tox-
icological profiles. Regulatory agencies therefore require
manufacturers to perform accurate preauthorization studies
to assess the quality, safety, and efficacy profiles of a new drug
product [197, 198].
Thus, despite the scientific community and private phar-
maceutical companies making considerable effort to develop
new nanoscale drug products, the approval rate for novel
nanomedicine products has not exceeded 10%, mainly
because of safety and efficacy profile failures during preclini-
cal and clinical studies [199]. Other nanosystems, such as
lipid nanoparticles, therefore become increasingly interesting
as they offer different advantages: undoubted matrix biocom-
patibility, solvent-free preparation methods, and, in some
cases, no need for high temperatures. In particular, the
presence of solvents may represent a shortcoming for an
Table 4: Continued.
Therapeutic/
technological aim
Patent number
Lipid
particle
type
Drug/active
delivered
Brief description Ref.
Antioxidant and
vitamin delivery
WO2006102768 SLN
Tocopherol
derivatives
A suitable SLN formulation is engineered with a
tocopherol derivative in the lipid matrix and a
water-soluble antibiotic in the aqueous phase
[169]
WO2011028757
SLN,
NLC
Tocotrienols
Lipid compositions that include tocotrienols are
engineered
[170]
WO2007103435
SLN,
NLC
Curcuminoids
Curcuminoid formulations with enhanced
bioavailability that are suitable for Alzheimer’s
disease treatment are produced
[171]
WO2010010431 [172]
WO2013105026 SLN Vitamins
SLN are employed as vehicles for vitamins,
especially vitamin D and retinoic acid, with
the aim of treating tuberculosis
[173]
WO9505164 SLN Ubidecarenone Ubidecarenone-loaded SLN are engineered [174]
IN718/CHE/2013 SLN Rutin
The treatment of diabetes and diabetic foot ulcers
in the form of an oral drug, and the treatment of
diabetic foot ulcers in the form of an ointment
[175]
IN79/DEL/2012 SLN
Vitamin D3 and
retinoic acid
Treatment of diseases like tuberculosis, age-related
macular degeneration, diabetic retinopathy, cancers,
hyperpigmentation, acne, and osteoporosis
[176]
Diagnostics
delivery
WO2017041609 SLN
Gadopentetate
dimeglumine
The MRI contrast agent gadopentetate
dimeglumine is loaded into SLN that are freeze-dried
with trehalose for easy intestinal uptake
[177]
WO2014037498 SLN
Paramagnetic
contrast agents
SLN are loaded with paramagnetic metals that are
chelated by diazepine and tetraazocyclododecane
compounds for in vivo applications
[178]
WO2014191467 SLN
Cyanine dye and
alkaline-earth metal
SLN are loaded with a fluorescent cyanine dye
and alkaline-earth metals that are complexed by
diazepine and tetraazocyclododecane compounds
for in vivo applications
[179]
Miscellaneous
WO2014058179 SLN —
LDL-like cationic SLN are suitable for
liver-targeted delivery, for both the diagnosis
and treatment of diseases
[180]
CN200910192863 SLN Emamectin
Emamectin benzoate-loaded SLN improve
chemical stability in hot and cold storage, reducing
the photolysis rate, prolonging efficacy time,
reducing dosage, and significantly improving
the insecticidal effect, as compared to raw emamectin
benzoate pesticides
[181]
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Table 5: Most important marketed and close-to-market products that contain lipid nano- and microparticles.
Manufacturer Trademark
Lipid
particles
type
Drug/active
Administration
route
Field of
application
Reached
development
stage
Ref.
Alpha RX
Ocusolin SLN Gentamicin Ocular Pharma Preclinical [183]
Zysolin SLN Tobramicin
Pulmonary,
parenteral
Pharma Preclinical [183]
Vansolin SLN Vancomicin Parenteral Pharma Preclinical [183, 184]
AmorePacific IOPE Line NLC
Ubidecarenone, omega-3
and omega-6 unsaturated
fatty acids
Dermal Cosmetic Marketed [124]
Bayer
HealthCare
Pharmaceuticals
Inc.
Cipro SLN Ciprofloxacin Oral Pharma Marketed [185, 186]
Beate Johnen
NLC deep effect eye
serum
NLC
Ubidecarenone, highly
active oligosaccharides
Dermal Cosmetic Marketed [124]
NLC deep effect
repair cream
NLC
Ubidecarenone, TiO2, and
highly active
oligosaccharides
Dermal Cosmetic Marketed [124]
NLC deep effect
reconstruction cream
NLC
Ubidecarenone, acetyl
hexapetide-8, highly active
oligosaccharides in
polysaccharide matrix, and
micronized plant collagen
Dermal Cosmetic Marketed [124]
Boehringer Mucosolvan Retard SLN Ambroxol Oral Pharma Marketed [184]
Chemisches
Laboratorium
(Dr. Richter)
NanoLipid Restore
CLR
NLC Black currant seed oil Dermal Cosmetic Marketed [124, 183]
NanoLipid Q10 CLR NLC
Ubidecarenone and black
currant seed oil
Dermal Cosmetic Marketed [124]
NanoLipid Basic
CLR
NLC — Dermal Cosmetic Marketed [124]
NanoLipid Repair
CLR
NLC
Black currant seed oil and
manuka oil
Dermal Cosmetic Marketed [124]
Dr. Rimpler
Cutanova Cream
Nanorepair Q10
NLC
Ubidecarenone,
polypeptide, Hibiscus
extract, ginger extract, and
ketosugar
Dermal Cosmetic Marketed [124]
Intensive Serum
Nanorepair Q10
NLC
Ubidecarenone,
polypeptide, Acmella
oleracea extract
Dermal Cosmetic Marketed [124]
Cutanova Cream
Nanovital Q10
NLC
Ubidecarenone, TiO2,
polypeptide, ursolic acid,
oleanolic acid, and
sunflower seed extract
Dermal Cosmetic Marketed [124]
Dr. Theiss
Olivenöl Anti Falten
Pflegekonzentrat
NLC
Olea europaea oil,
panthenol, Acacia senegal,
tocopheryl acetate
Dermal Cosmetic Marketed [124]
Olivenöl
Augenpflegebalsam
NLC
Olea europaea oil, Prunus
amygdalus Dulcis oil,
hydrolyzed milk protein,
tocopheryl acetate, Rhodiola
rosea root extract, and
caffeine
Dermal Cosmetic Marketed [124]
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industrial process, as solvents can affect the stability of active
compounds, their removal may be expensive, and they may
induce toxicological (residues) and environmental problems.
There is a certain typical time frame between the inven-
tion of a system and its introduction to the market. From
the invention of liposomes in 1965, it took about 20 years
for them to reach the cosmetic market (antiaging product
“Capture” launched by Dior in 1986) and 25 years for the
first pharmaceutical product (Alveofact by Dr. Karl Thomae
GmbH Germany). Based on this, and taking 1992 as year of
the invention of SLN, one could have expected the first phar-
maceutical products to arrive around 2016-2020. However,
only two lipid nanoparticle-based pharmaceutical products
have been marketed to date. Moreover, after the financial
crisis of 2008, companies have rethought their investment
and product development policies and have become more
conservative. This may have influenced the clinical testing
of lipid nanoparticulate systems [182].
6. Conclusions
Research into lipid nano- and microparticles has been per-
formed for nearly 25 years. Patenting activity has grown,
and, at the same time, the use of nanotechnology as an
innovative tool to treat diseases has boomed, while poten-
tial commercial interest in biocompatible materials and
solvent-free preparation techniques has increased as well.
In fact, microemulsion templates were the first technique
Table 5: Continued.
Manufacturer Trademark
Lipid
particles
type
Drug/active
Administration
route
Field of
application
Reached
development
stage
Ref.
Isabelle Lancray
Surmer Crème
Legère
Nano-Protection
NLC
Kukui nut oil, Monoi Tiare
Tahiti®, pseudopeptide,
coconut milk, and wild
indigo
Dermal Cosmetic Marketed [124]
Surmer Crème Riche
Nano-Restructurante
NLC
Kukui nut oil, Monoi Tiare
Tahiti®, pseudopeptide,
coconut milk, wild indigo,
and tamanol
Dermal Cosmetic Marketed [124]
Surmer Elixir du
Beauté
Nano-Vitalisant
NLC
Kukui nut oil, Monoi Tiare
Tahiti®, pseudopeptide,
coconut milk, and wild
indigo
Dermal Cosmetic Marketed [124]
Surmer Masque
Crème
Nano-Hydratant
NLC
Kukui nut oil, Monoi Tiare
Tahiti®, pseudopeptide,
coconut milk, wild indigo,
and tamanol
Dermal Cosmetic Marketed [124]
Surmer Crème
Contour Des Yeux
Nano-Remodelante
NLC
Kukui nut oil,
pseudopeptide, hydrolyzed
wheat protein, Ximenia
americana seed oil, and
tamanol
Dermal Cosmetic Marketed [124]
Kemin
Industries
FloraGlo NLC Lutein Oral Food Marketed [187]
La Prairie Swiss Cellular White NLC
Glycoproteins, Panax
ginseng root extract,
Equisetum arvense extract,
Camellia sinensis leaf
extract, and Viola tricolor
extract
Dermal Cosmetic Marketed [124]
Pharmasol TransoPlex
Cationic
SLN
— Parenteral Pharma Preclinical [183]
Pharmatec
(Sigmoid
Pharma)
CyCol SLN Cyclosporine Oral Pharma Preclinical [183, 188]
Scholl
Regenerations
Creme Intensiv
NLC
Macadamia ternifolia seed
oil, avocado oil, urea, and
blackcurrant seed oil
Dermal Cosmetic Marketed [124]
Yamanouchi Nanobase SLN — Dermal Cosmetic Marketed [183]
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that was patented, by Gasco et al. in 1993, for lipid nano-
particle preparation. Since then, an increasing number of
patents were filed, up to 2010. Great importance should be
given to the patents filed by Müller and Lucks in 1996. They
are a milestone in lipid nanoparticle research as they adapted
HPH, which is a well-established industrial technique that is
currently employed for nanoemulsion preparation, for use in
SLN, NLC, and LDC production. Since then, several techno-
logical patents on alternative preparation techniques have
been filed to overcome the limitations of existing methods.
Furthermore, an increasing number of composition and
usage patents have been filed, especially since 2000. This
can probably be correlated to the discovery of new practical
pharmacological and technological fields in which lipid
nanoparticle technologies can be successfully used. In fact, a
significant number of dermal drug delivery patents have been
filed that demonstrate a range of advantages offered by these
delivery systems, including chemical stabilization and the
increased skin penetration/permeation of drugs. This latter
aspect is mainly due to the lipid occlusion effect on skin.
However, a significant number of oral drug delivery patents
are currently being filed. This is probably because the oral
route is the most widespread and acceptable for therapy,
and Biopharmaceutics Classification System (BCS) class IV
drugs suffer from several bioavailability issues. Moreover,
some drug delivery challenges can be considered opportuni-
ties for lipid nanoparticles. Firstly, lipid nanoparticles are
seen to be an interesting means of overcoming the BBB
because of their lipid composition and ease of functionaliza-
tion. Secondly, a number of mechanisms that are linked to
lipid nanoparticle use can benefit cancer therapy. Some of
the most intriguing approaches in these fields have been the
subject of patents. Finally, a considerable number of patents
have focused on macromolecule delivery; nucleic acids and
proteins are the future of pharmacological therapy, and both
present comparable issues with stability, poor bioavailability,
and high molecular weight, which hamper their use in cur-
rent therapies and can also be a technological drawback for
lipid nano- and microparticle loading.
Most marketed lipid nano- and microparticle-based
products are currently licensed as cosmetics, while the
development of pharmaceutical drug delivery systems, espe-
cially for oral and parenteral use, is still mostly, with some
exceptions, at the clinical or even preclinical stage. The
main obstacle to reaching the market in the pharmacolog-
ical field seems to be the regulatory aspect: expensive clin-
ical studies are required, and these costs should be justified
by significant clinical results and advantages over commer-
cial formulations and high reproducibility, as well as the
total safety of all the materials and formulations employed.
Although Europe and USA are the leading countries in terms
of patent applications, it is worth noting that there has been
an increase in the patenting activity of Emerging Countries
in recent years.
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